{"id":297,"date":"2015-12-28T09:05:51","date_gmt":"2015-12-28T09:05:51","guid":{"rendered":"http:\/\/www.farmacovigilanciacanarias.org\/noticias\/?p=297"},"modified":"2016-12-15T14:02:40","modified_gmt":"2016-12-15T14:02:40","slug":"nota-informativa-muh-fv-122015","status":"publish","type":"post","link":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/2015\/12\/28\/nota-informativa-muh-fv-122015\/","title":{"rendered":"Nota Informativa MUH (FV), 12\/2015"},"content":{"rendered":"<table class=\"tablaHome\">\n<tbody>\n<tr>\n<td><a href=\"http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2015\/NI-MUH_FV_12-fingolimod-gilenya.htm\">Fingolimod (\u25bcGilenya): recomendaciones sobre los riesgos relacionados con su efecto inmunosupresor<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Fingolimod (\u25bcGilenya): recomendaciones sobre los riesgos relacionados con su efecto inmunosupresor<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-297","post","type-post","status-publish","format-standard","hentry","category-seguridad"],"_links":{"self":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/comments?post=297"}],"version-history":[{"count":2,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/297\/revisions"}],"predecessor-version":[{"id":299,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/297\/revisions\/299"}],"wp:attachment":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/media?parent=297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/categories?post=297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/tags?post=297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}